You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

~ Buy the TALICIA (amoxicillin; omeprazole magnesium; rifabutin) Drug Profile, 2024 PDF Report in the Report Store ~

TALICIA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Talicia, and what generic alternatives are available?

Talicia is a drug marketed by Redhill and is included in one NDA. There are seven patents protecting this drug.

This drug has thirty patent family members in twenty-five countries.

The generic ingredient in TALICIA is amoxicillin; omeprazole magnesium; rifabutin. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; omeprazole magnesium; rifabutin profile page.

DrugPatentWatch® Generic Entry Outlook for Talicia

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 1, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TALICIA?
  • What are the global sales for TALICIA?
  • What is Average Wholesale Price for TALICIA?
Summary for TALICIA
International Patents:30
US Patents:7
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for TALICIA
What excipients (inactive ingredients) are in TALICIA?TALICIA excipients list
DailyMed Link:TALICIA at DailyMed
Drug patent expirations by year for TALICIA
Drug Prices for TALICIA

See drug prices for TALICIA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TALICIA
Generic Entry Date for TALICIA*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
NDA:
Dosage:
CAPSULE, DELAYED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TALICIA

TALICIA is protected by seven US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TALICIA is ⤷  Sign Up.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TALICIA

Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Rifabutin-based compositions and methods for treating Helicobacter pylori infection
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF HELICOBACTER PYLORI INFECTION USING THE ADMINISTERED DOSAGE FORMS IN ADULTS WITH DIFFERENT BODY MASS INDEX DETERMINATIONS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF HELICOBACTER PYLORI INFECTION IN ADULTS USING SPECIFIED DOSAGE FORM

Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS

Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS

Pharmaceutical compositions for the treatment of Helicobacter pylori
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF H. PYLORI INFECTION IN ADULTS

FDA Regulatory Exclusivity protecting TALICIA

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Redhill TALICIA amoxicillin; omeprazole magnesium; rifabutin CAPSULE, DELAYED RELEASE;ORAL 213004-001 Nov 1, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TALICIA

When does loss-of-exclusivity occur for TALICIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 14216373
Patent: Pharmaceutical compositions for the treatment of Helicobacter pylori
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2015019264
Patent: composições farmacêuticas para o tratamento de helicobacter pylori
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 00763
Patent: COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT D'HELICOBACTER PYLORI (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 15002253
Patent: Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
Estimated Expiration: ⤷  Sign Up

China

Patent: 5163743
Patent: Pharmaceutical compositions for the treatment of helicobacter pylori
Estimated Expiration: ⤷  Sign Up

Patent: 9893516
Patent: 用于治疗幽门螺杆菌的药物组合物 (Pharmaceutical compositions for treatment of Helicobacter pylori)
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0191559
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 56149
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 56149
Patent: COMPOSITIONS PHARMACEUTIQUES DESTINÉES AU TRAITEMENT D'HELICOBACTER PYLORI (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 17645
Patent: 用於治療幽門螺桿菌的藥物組合物 (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 52411
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 0387
Patent: תכשירי רוקחות לטיפול בהליקובקטר פילורי (Pharmaceutical compositions for the treatment of helicobacter pylori)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 94529
Estimated Expiration: ⤷  Sign Up

Patent: 16508516
Patent: ピロリ菌治療用医薬組成物
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 8536
Patent: COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE HELICOBACTER PYLORI. (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI.)
Estimated Expiration: ⤷  Sign Up

Patent: 15010490
Patent: COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE HELICOBACTER PYLORI. (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI.)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 1754
Patent: Pharmaceutical compositions for the treatment of helicobacter pylori
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 015501783
Patent: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 56149
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 56149
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 71400
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ОТ HELICOBACTER PYLORI (PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI)
Estimated Expiration: ⤷  Sign Up

Patent: 15138708
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ОТ HELICOBACTER PYLORI
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201506318Q
Patent: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 56149
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2062357
Estimated Expiration: ⤷  Sign Up

Patent: 150118176
Patent: 헬리코박터 파일로리 치료용 약제학적 조성물 (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 44406
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 0249
Patent: ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ ВІД HELICOBACTER PYLORI (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI)
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TALICIA around the world.

Country Patent Number Title Estimated Expiration
Hong Kong 1217645 用於治療幽門螺桿菌的藥物組合物 (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI) ⤷  Sign Up
Poland 2956149 ⤷  Sign Up
Israel 240387 תכשירי רוקחות לטיפול בהליקובקטר פילורי (Pharmaceutical compositions for the treatment of helicobacter pylori) ⤷  Sign Up
China 105163743 Pharmaceutical compositions for the treatment of helicobacter pylori ⤷  Sign Up
Ukraine 120249 ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ ВІД HELICOBACTER PYLORI (PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI) ⤷  Sign Up
Cyprus 1122113 ⤷  Sign Up
Portugal 2956149 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.